Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease - PubMed (original) (raw)
Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease
T Parrello et al. J Immunol. 2000.
Abstract
Crohn' s disease (CD) is a chronic intestinal inflammatory disorder characterized by aberrant mucosal Th1 cell activation and production of IL-12, the major Th1-driving factor. The T cell response to IL-12 is dependent on the expression of a specific receptor composed of two subunits, termed IL-12Rbeta1 and IL-12Rbeta2. The content of IL-12Rbeta2, as measured at the mRNA level, is crucial in regulating Th1 differentiation. In this study we therefore investigated IL-12Rbeta2 RNA transcripts in CD. IL-12Rbeta2 expression was increased in active CD as well as Helicobacter pylori (HP)-associated gastritis and Salmonella colitis compared with that in inactive CD, ulcerative colitis, noninflammatory controls, and celiac disease. In contrast, IL-12Rbeta1 transcripts were expressed at comparable levels in all samples. In CD, IL-12Rbeta2 expression strictly correlated with tyrosine phosphorylation of STAT4, a key component of the IL-12-dependent Th1 polarization. This was associated with a pronounced expression of IFN-gamma. Transcripts for IL-12/p40 were detected in CD, HP-positive, and Salmonella colitis patients, but not in celiac disease, indicating that IL-12Rbeta2 up-regulation occurs only in IL-12-associated Th1 gastrointestinal diseases. Finally, we showed that stimulation of lamina propria mononuclear cells with IL-12 enhanced IL-12Rbeta2, suggesting that IL-12 regulates IL-12Rbeta2 expression in human gastrointestinal mucosa. The data show that the signaling pathway used by IL-12 to induce Th1 differentiation is increased at the site of disease in CD, further supporting the view that IL-12/IL-12R signals contribute to the inflammatory response in this condition.
Similar articles
- Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling.
Nishikomori R, Usui T, Wu CY, Morinobu A, O'Shea JJ, Strober W. Nishikomori R, et al. J Immunol. 2002 Oct 15;169(8):4388-98. doi: 10.4049/jimmunol.169.8.4388. J Immunol. 2002. PMID: 12370372 - Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease.
Coccia EM, Remoli ME, Di Giacinto C, Del Zotto B, Giacomini E, Monteleone G, Boirivant M. Coccia EM, et al. Gut. 2005 Nov;54(11):1558-64. doi: 10.1136/gut.2004.062174. Epub 2005 Aug 16. Gut. 2005. PMID: 16105891 Free PMC article. - Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells.
Verhagen CE, de Boer T, Smits HH, Verreck FA, Wierenga EA, Kurimoto M, Lammas DA, Kumararatne DS, Sanal O, Kroon FP, van Dissel JT, Sinigaglia F, Ottenhoff TH. Verhagen CE, et al. J Exp Med. 2000 Aug 21;192(4):517-28. doi: 10.1084/jem.192.4.517. J Exp Med. 2000. PMID: 10952721 Free PMC article. - Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication.
Peluso I, Pallone F, Monteleone G. Peluso I, et al. World J Gastroenterol. 2006 Sep 21;12(35):5606-10. doi: 10.3748/wjg.v12.i35.5606. World J Gastroenterol. 2006. PMID: 17007011 Free PMC article. Review. - Food allergy, coeliac disease and chronic inflammatory bowel disease in man.
Peña AS, Crusius JB. Peña AS, et al. Vet Q. 1998;20 Suppl 3:S49-52. Vet Q. 1998. PMID: 9689726 Review.
Cited by
- An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.
Stallmach A, Marth T, Weiss B, Wittig BM, Hombach A, Schmidt C, Neurath M, Zeitz M, Zeuzem S, Abken H. Stallmach A, et al. Gut. 2004 Mar;53(3):339-45. doi: 10.1136/gut.2003.020107. Gut. 2004. PMID: 14960512 Free PMC article. - Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.
Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Aggeletopoulou I, et al. World J Gastroenterol. 2018 Sep 28;24(36):4093-4103. doi: 10.3748/wjg.v24.i36.4093. World J Gastroenterol. 2018. PMID: 30271076 Free PMC article. - Genetic and pathogenetic insights into inflammatory bowel disease.
Pallone F, Blanco Gdel V, Vavassori P, Monteleone I, Fina D, Monteleone G. Pallone F, et al. Curr Gastroenterol Rep. 2003 Dec;5(6):487-92. doi: 10.1007/s11894-003-0038-2. Curr Gastroenterol Rep. 2003. PMID: 14602058 Review. - T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease.
Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, Sakuraba A, Hitotsumatsu O, Ogata H, Koganei K, Fukushima T, Kanai T, Watanabe M, Ishii H, Hibi T. Matsuoka K, et al. Gut. 2004 Sep;53(9):1303-8. doi: 10.1136/gut.2003.024190. Gut. 2004. PMID: 15306590 Free PMC article. - No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases.
Malamut G, Cabane C, Dubuquoy L, Malapel M, Dérijard B, Gay J, Tamboli C, Colombel JF, Desreumaux P. Malamut G, et al. Dig Dis Sci. 2006 Aug;51(8):1443-53. doi: 10.1007/s10620-006-9116-2. Epub 2006 Jul 13. Dig Dis Sci. 2006. PMID: 16838116
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous